FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to a pharmaceutical composition and methods of using it in treating insufficient eye lubrication, related symptoms or adverse conditions related to insufficient eye lubrication. The pharmaceutical composition contains human PRG4, its wetting fragment, a homologue or an isoform suspended in ophthalmologically acceptable balanced saline. The pharmaceutical composition can also contain one or more ophthalmologically acceptable agents specified in a group consisting of a sedative, an excipient, a binding agent, a vasoconstrictor, an emollient, sodium hyaluronate, hyaluronic acid and surface active phospholipids in a pharmaceutically acceptable carrier for topical use.
EFFECT: group of inventions provides treating the diseases related to impaired corneal and conjunctival wetting.
15 cl, 10 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION AND METHOD FOR TREATMENT OF EYE DISEASE ASSICIATED WITH NUCLEIC ACIDS | 2012 |
|
RU2642609C2 |
| METHODS AND COMPOSITIONS FOR TREATING DRY EYE DISEASE AND OTHER EYE DISEASES | 2016 |
|
RU2691412C2 |
| VITAMIN D MICROEMULSIONS AND THEIR APPLICATIONS | 2019 |
|
RU2812079C2 |
| OPHTHALMIC COMPOSITIONS AND METHODS OF TREATING EYES | 2005 |
|
RU2410081C2 |
| OPHTHALMIC PHARMACEUTICAL COMPOSITIONS | 2018 |
|
RU2818087C2 |
| VARIANT AAV, COMPOSITIONS AND METHODS, IN WHICH IT IS USED, AS WELL AS METHODS OF ITS APPLICATION FOR TRANSFER OF GENES INTO CELLS, ORGANS AND TISSUES | 2014 |
|
RU2697444C2 |
| DEMETHYLATION FOR TREATMENT OF EYE DISEASE | 2019 |
|
RU2804300C2 |
| OPHTHALMIC COMPOSITION CONTAINING CYCLOSPORINE AND TREHALOSE | 2015 |
|
RU2700927C2 |
| COMPOSITIONS AND METHODS FOR EYE TREATMENT | 2019 |
|
RU2793736C2 |
| OPHTHALMIC COMPOSITION | 2017 |
|
RU2749723C2 |
